Gilioli da Costa Nunes Giovanna, Cezar Aquino de Moraes Francisco, Carvalho de Almeida Aline Beatriz, Goes Costa Felipe, Duarte de Andrade Junior Luiz Fernando, Sabino Hupp Maria Vitória, Rotondano Assunção Ruan, Rodrigues Fernandes Marianne, Emanuel Batista Dos Santos Sidney, Pereira Carneiro Dos Santos Ney
Research Center of Oncology, Federal University of Pará Belém, Belém 66073-000, PA, Brazil.
Faculty of Medicine, Federal University of Pará Belém, Belém 66073-000, PA, Brazil.
Int J Mol Sci. 2025 Apr 4;26(7):3369. doi: 10.3390/ijms26073369.
Multiple myeloma ranks as the second most common hematopoietic malignancy in terms of both incidence and mortality. Prognostic stratification is critical for optimizing therapeutic strategies, as certain genetic alterations can significantly influence disease progression and treatment response. The meta-analysis analyzed data from 3421 multiple myeloma patients and 14,720 controls. PubMed, Web of Science, and Scopus were used as databases. Associations between the SNPs and multiple myeloma were calculated as a measure of pooled odds ratios (ORs) and 95% confidence intervals. Statistical analysis was performed using Review Manager (RevMan). rs4487645 A/C genotype (OR = 1.35; 95% CI: 1.24-1.46; < 0.00001; I = 0%), rs1052501 G/G genotype (OR = 1.21; 95% CI: 0.98-1.50; = 0.08; I = 64%) rs1052501 A/G genotype (OR = 1.23; 95% CI: 1.13-1.34; < 0.00001; I = 0%), rs6746082 A/A genotype (OR = 1.10; 95% CI: 1.01-1.20; = 0.03; I = 45%), and rs1544410 A/G genotype (OR = 1.87; 95% CI: 1.04-3.36; = 0.04; I = 0%) increased multiple myeloma risk. Our study concludes that , , , and may serve as predictive biomarkers for MM risk.
就发病率和死亡率而言，多发性骨髓瘤是第二常见的造血系统恶性肿瘤。预后分层对于优化治疗策略至关重要，因为某些基因改变可显著影响疾病进展和治疗反应。该荟萃分析分析了来自3421例多发性骨髓瘤患者和14720例对照的数据。使用PubMed、科学网和Scopus作为数据库。计算单核苷酸多态性（SNP）与多发性骨髓瘤之间的关联，作为合并比值比（OR）和95%置信区间的度量。使用Review Manager（RevMan）进行统计分析。rs4487645 A/C基因型（OR = 1.35；95%CI：1.24 - 1.46；P < 0.00001；I² = 0%）、rs1052501 G/G基因型（OR = 1.21；95%CI：0.98 - 1.50；P = 0.08；I² = 64%）、rs1052501 A/G基因型（OR = 1.23；95%CI：1.13 - 1.34；P < 0.00001；I² = 0%）、rs6746082 A/A基因型（OR = 1.10；95%CI：1.01 - 1.20；P = 0.03；I² = 45%）和rs1544410 A/G基因型（OR = 1.87；95%CI：1.04 - 3.36；P = 0.04；I² = 0%）会增加多发性骨髓瘤风险。我们的研究得出结论， 、 、 和 可能作为MM风险的预测生物标志物。 （注：原文中部分基因相关表述未给出具体内容，用 代替）
